

Fact Sheet

Juno Selection Fund – March 2025



This is a marketing communication

MANAGER COMMENTARY

The positive share price performance of January 2025 was abruptly reversed this month. The direct reason is the major uncertainty caused by the unpredictable policies on import tariffs. The share prices of pharmaceutical and medical technology companies also fell because investors are struggling to evaluate the impact of changed procedures and regulations on demand in the US market. Shares of **Camurus**, **Stratec**, **Sartorius** and **Bachem** lost approximately 10% each. In the meantime, Germany has announced that it will commence borrowing heavily for overdue investments in defense and infrastructure, which caused European interest rates to suddenly increase to 2.75%. Defense and banking shares benefited from this, but we do not invest in either sector. Turbulence in the global economy and the rise in interest rates in Europe, caused a sharp fall in the US dollar in March. Our companies that have significant dollar-denominated income, faced selling pressure in their shares as a result. **Biogaia** and **Paradox** in particular, saw a 10% decline in their share prices last month. **Technogym's** strong 2024 results translated into a welcome rising share price. **Cewe** also posted a positive return, partly as a result of the detailed publication of its 2024 results and the cautiously positive outlook.

FUND PROFILE


Fund size	€ 238 million
Net asset value*	€ 413.13
Equity exposure	82%
# Portfolio companies	15
Weighted average market cap	€ 2.9 billion

*per participation

Initial investment from	€150,000.-
Add-ons from	€25,000.-
Management Fee	1.2% p/a
Performance Fee	10%
High Water Mark	Perpetual (€543.46; 31/12/21)
Entry Fee	1%
Exit Fee	0.5%
TER	1.25% (2023)
Legal Status	Mutual Fund
Fund Currency	EUR
Valuation	Monthly
Inception	January 11, 2008
Reporting	Net
Licence	AIFMD
Depository	State Street Bank
ISIN	NL0010188017
Bloomberg	JUNOSEL NA
Reuters	LP68041261

PERFORMANCE UP TO MARCH 31, 2025

Past results are no guarantee for future performance



Source: Juno Investment Partners B.V., monthly net asset value, excluding entry and exit fees; MSCI

10 YR PERFORMANCE IN FIGURES

	1 mo	YTD	1 yr	3 yrs	5 yrs	10 yrs	since inception
Juno Selection Fund	-5.3%	-0.3%	-4.5%	-10.0%	19.1%	58.3%	313.1%
MSCI Eur. Small Cap Euro (Net)	-3.2%	1.3%	3.4%	3.7%	70.3%	68.3%	226.8%

ESG-PROFILE

SFDR-classification: Article 8

"Article 8"-products promote social and/or ecological characteristics, but do not have sustainable investing as their main objective.

For more information on Juno's sustainability policy, [click here](#). Juno Investment Partners' Principal Adverse Impact (PAI) statement can be found [here](#).



Frans Jurgens
1969



Lennart Smits
1978



Bobby Bader
1992


PORTFOLIO – TOP 5

Name	Sector
Paradox Interactive AB	Entertainment
Medacta Group SA	Health Care Equipment & Supplies
Technogym SpA	Leisure Products
Cewe Stiftung & Co KGaA	Commercial Services & Supplies
Bachem Holding AG	Life Sciences Tools & Services


PORTFOLIO – CURRENCY



PORTFOLIO – SECTORS



PORTFOLIO – COUNTRIES



STRATEGY

Juno invests in highly profitable listed companies, with predictable earnings growth and preferably with management or a (founding) family as their main shareholders. Listed European family-owned companies operate with a longer term perspective and are more successful than non-family-owned companies^{1/}.

Juno aims to achieve capital growth by investing in a highly concentrated portfolio of European companies. Selection takes place based on its proprietary fundamental, bottom-up analysis including on-site visits.

A high or rising return on capital and large free cash flows are good indicators of strong companies that we are interested in. We invest with a time horizon of 3 to 5 years.

The Juno Selection Fund focuses on companies with a market cap between €250 million and €4 billion at the moment of initial investment.

1/ Source: Stiftung Familienunternehmen, A. Gregorič, M.S. Rapp, I. Requejo "Listed Family Firms in Europe, Relevance, Characteristics and Performance", 2022.

DISCLAIMER

Attention: This is a marketing communication. The information about financial markets or specific financial instruments in this document is solely intended to provide you with information about the Juno portfolio management team's view on the financial markets. This information is not an investment recommendation, nor an offer or invitation to buy or sell a financial instrument. The decision to participate in this investment fund should be taken solely on the basis of the prospectus and the key information document. You can consult these documents under 'Fund Documents' on the Fund's web page.

There are risks associated with this investment. The value of your investment may fluctuate, and past performance is no guarantee of future performance. The fund invests in stocks and stocks have a higher risk profile than bonds. The fund invests in a limited number of companies, which may lead to stronger fluctuations in the fund's net asset value than would have been the case if the fund were less concentrated. For an overview of the risks of this fund, we refer to the risk section included in the prospectus.

Juno obtains its information from sources deemed reliable, such as annual reports and other official publications, and has taken every care to ensure that the information on which it bases its view is not incorrect or misleading. The net returns presented in this communication are based on the

Don't take any unnecessary risks

1

2

3

4

5

6

7

Lower riskHigher risk

risk indicator

Read the Key Information Document

THIS IS A MANDATORY ANNOUNCEMENT